Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-7-23
pubmed:abstractText
Vgamma9/Vdelta2 (gammadelta) T cells play a major role in innate immunity against microbes, stressed, and tumor cells. They represent less than 5% of peripheral blood lymphocytes but can be activated and expanded in vitro by aminobisphosphonates (ABP)-treated monocytes. The aim of this work was to determine whether ABP-treated dendritic cells (DCs) can also activate gammadelta T cells and regulate immune responses mediated by conventional alphabeta T cells. Highly purified immature (iDC) and mature DC (mDC) were generated from peripheral blood monocytes of healthy donors and incubated with zoledronic acid (Zol) for 24 hours. Zol-treated iDC and mDC retained their immunostimulatory properties and induced the vigorous expansion of central memory and effector memory gammadelta T cells. gammadelta T cells displayed antitumor activity and appropriate cell surface antigens to target secondary lymphoid organs and exert costimulatory activity. Antigen-specific MHC-restricted immune responses, mediated by conventional alphabeta T cells, were improved by the concurrent gammadelta T-cell activation. In conclusion, large numbers of gammadelta T cells with effector and costimulatory activities are rapidly generated by Zol-treated iDC/mDC. This strategy is worthy of further investigation to improve adoptive cell therapy and vaccine interventions against tumors and infections.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
110
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
921-7
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17403919-Adjuvants, Immunologic, pubmed-meshheading:17403919-Bone Density Conservation Agents, pubmed-meshheading:17403919-Cancer Vaccines, pubmed-meshheading:17403919-Cell Proliferation, pubmed-meshheading:17403919-Cells, Cultured, pubmed-meshheading:17403919-Dendritic Cells, pubmed-meshheading:17403919-Diphosphonates, pubmed-meshheading:17403919-Histocompatibility Antigens, pubmed-meshheading:17403919-Humans, pubmed-meshheading:17403919-Imidazoles, pubmed-meshheading:17403919-Immunity, Innate, pubmed-meshheading:17403919-Immunologic Memory, pubmed-meshheading:17403919-Immunotherapy, Adoptive, pubmed-meshheading:17403919-Lymphocyte Activation, pubmed-meshheading:17403919-Monocytes, pubmed-meshheading:17403919-Neoplasms, pubmed-meshheading:17403919-Receptors, Antigen, T-Cell, alpha-beta, pubmed-meshheading:17403919-Receptors, Antigen, T-Cell, gamma-delta, pubmed-meshheading:17403919-T-Lymphocytes, pubmed-meshheading:17403919-Time Factors
pubmed:year
2007
pubmed:articleTitle
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid.
pubmed:affiliation
Division of Hematology, University of Turin, Via Genova 3, 10126 Turin, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't